Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Melatonin may not significantly reduce inflammation in diabetic CKD patients
Last updated August 16, 2026
Key finding
There was no significant difference in TAC levels after the intervention.
This study investigated the effects of melatonin supplementation on oxidative stress and inflammatory markers in diabetic patients with chronic kidney disease, finding no significant changes in the measured outcomes.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study investigated the effects of melatonin supplementation on oxidative stress and inflammatory markers in diabetic patients with chronic kidney disease, finding no significant changes in the measured outcomes.
Clinical relevance
Understanding the impact of melatonin on oxidative stress and inflammation is crucial for managing diabetic patients with chronic kidney disease. This study's findings suggest that melatonin supplementation may not provide the anticipated benefits in reducing these health risks, highlighting the need for further research in this area.
Keep in mind
The study may have limited generalizability due to the specific population studied. Sample size and duration may not have been sufficient to detect significant changes. Outcomes measured did not show clinically meaningful differences.
Published in
Journal Reference
Publication details and source links for this paper.
Sara S, Amirahmad N, Monir SH, et al. Effects of Melatonin Supplementation on Oxidative Stress and Inflammatory Markers in Diabetic Patients with Chronic Kidney Disease: A Double-Blind Clinical Trial. BMC Nutrition. 2025;11:34. doi:10.1186/s40795-025-01026-0
Main Effects
Total Antioxidant Capacity (TAC) levels showed no significant difference after the intervention.
Total Oxidative Stress (TOS) levels decreased after 10 weeks, but this change was not statistically significant.
Malondialdehyde (MDA) levels did not show a statistically significant change post-intervention.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Melatonin and C-reactive protein, Interleukin-6 (IL-6), Malondialdehyde (MDA), and 2 more.
This study contributes evidence to
Primary intervention
Melatonin
Primary outcomes
- C-reactive protein
- Interleukin-6 (IL-6)
- Malondialdehyde (MDA)
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
1
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 63
1
Related topics
5
Evidence pairs
59
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 1 direct semantic evidence topic
Topic contributions
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
Inflammatory and Vascular Markers
matched_outcome
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerTotal Antioxidant Capacity (TAC)
Melatonin → Total Antioxidant Capacity (TAC)
Melatonin → Total Antioxidant Capacity (TAC)
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerTotal oxidant status in plasma
Melatonin → Total oxidant status in plasma
Melatonin → Total oxidant status in plasma
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Melatonin supplementation did not significantly alter Total Antioxidant Capacity.
- No significant changes in inflammatory markers like Interleukin-6 were observed.
- Total Oxidative Stress levels decreased but lacked statistical significance.
Who this applies to
- Diabetic patients with chronic kidney disease.
- Adults aged 18 and older with chronic health conditions.
Keep in Mind
- Results may not apply to populations outside the study's demographic.
- The lack of significant findings suggests caution in recommending melatonin for this purpose.
- Further research is needed to explore potential benefits in different populations or with different dosages.
Between the Lines
- The study may have limited generalizability due to the specific population studied.
- Sample size and duration may not have been sufficient to detect significant changes.
- Outcomes measured did not show clinically meaningful differences.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Melatonin and Inflammatory Markers, Melatonin and Oxidative Stress Markers.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Supplements
Melatonin → Inflammatory Markers
Supplements
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
View evidenceSupplements
Melatonin → Oxidative Stress Markers
Supplements
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Inflammatory Markers Evidence Hub
All studies measuring Inflammatory Markers
2 studies
outcome_hubMeasures Inflammatory Markers as a key outcome.
Melatonin Evidence Hub
All studies on Melatonin
2 studies
intervention_hubContributes to Melatonin evidence base.
Oxidative Stress Markers Evidence Hub
All studies measuring Oxidative Stress Markers
2 studies
outcome_hubMeasures Oxidative Stress Markers as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Melatonin and C-reactive protein
Intervention: MelatoninOutcome: C-reactive protein
2 results
All studies on Melatonin and Malondialdehyde (MDA)
Intervention: MelatoninOutcome: Malondialdehyde (MDA)
2 results
All studies on Melatonin
Intervention: Melatonin
2 results
All studies measuring C-reactive protein
Outcome: C-reactive protein
2 results
All studies measuring Malondialdehyde (MDA)
Outcome: Malondialdehyde (MDA)
2 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Melatonin improve malondialdehyde (mda)?
Moderate Evidence
Melatonin may improve Malondialdehyde (MDA).
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Malondialdehyde (MDA)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Only one supporting study is available.
- Population details are unavailable.
Does Melatonin improve total antioxidant capacity (tac)?
Moderate Evidence
Melatonin may improve Total Antioxidant Capacity (TAC).
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Total Antioxidant Capacity (TAC)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Only one supporting study is available.
- Population details are unavailable.
Does Melatonin improve c-reactive protein?
Moderate Evidence
Current evidence does not show a clear benefit of Melatonin for C-reactive protein.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
C-reactive protein
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Population details are unavailable.
Does Melatonin improve interleukin-6 (il-6)?
Emerging Evidence
Current evidence does not show a clear benefit of Melatonin for Interleukin-6 (IL-6).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Interleukin-6 (IL-6)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Melatonin supplementation may improve blood pressure and obesity indicators in type 2 diabetes patientsMelatonin improves glycemic control in type 2 diabetes patientsMelatonin gel improves healing of diabetic foot ulcersMelatonin may improve antioxidant levels in diabetes patients with gum disease.Melatonin shows little effect on glycemic control in type 2 diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.